Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 4
Submit an article Journal homepage
133
Views
10
CrossRef citations to date
0
Altmetric
Theme: ADHD - Review

Individual treatment response in attention-deficit/hyperactivity disorder: broadening perspectives and improving assessments

Paul Hodgkins Global Health Economics and Outcomes Research, Shire Development, LLC, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA. [email protected]; Global Health Economics and Outcomes Research, Shire Development, LLC, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA. [email protected]
,
Ralf W Dittmann Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
Shaw Sorooshian Shire AG, Nyon, Switzerland; Shire AG, Nyon, Switzerland
&
Tobias Banaschewski Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Pages 425-433 | Published online: 09 Jan 2014

References

  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. American Psychiatric Association, Washington, DC, USA (2000).
  • Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 9(3), 490–499 (2012).
  • Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 164(6), 942–948 (2007).
  • Hebebrand J, Buitelaar JK. On the way to DSM-V. Eur. Child Adolesc. Psychiatry 20(2), 57–60 (2011).
  • WHO. International Classification of Diseases (ICD-10). WHO, Geneva, Switzerland, 378–379 (1992).
  • Barkley RA, Cunningham CE, Gordon M et al. ADHD symptoms vs. impairment: revisited. ADHD Report 14(2), 1–9 (2006).
  • Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J. Adolesc. Health 46(3), 209–217 (2010).
  • DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J. Am. Acad. Child Adolesc. Psychiatry 40(5), 508–515 (2001).
  • Wilson JM, Marcotte AC. Psychosocial adjustment and educational outcome in adolescents with a childhood diagnosis of attention deficit disorder. J. Am. Acad. Child Adolesc. Psychiatry 35(5), 579–587 (1996).
  • Coghill D. Pragmatic measures in paediatric psychopharmacology – are we getting it right? Eur. Neuropsychopharmacol. 21(8), 571–583 (2011).
  • Biederman J, Faraone SV, Spencer T et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 150(12), 1792–1798 (1993).
  • Klein RG, Mannuzza S, Olazagasti MA et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch. Gen. Psychiatry 69(12), 1295–1303 (2012).
  • Doshi JA, Hodgkins P, Kahle J et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J. Am. Acad. Child Adolesc. Psychiatry 51(10), 990–1002.e2 (2012).
  • Bernardi S, Faraone SV, Cortese S et al. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol. Med. 42(4), 875–887 (2012).
  • Brod M, Perwien A, Adler L, Spencer T, Johnston J. Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Prim. Psychiatry 12(6), 58–64 (2005).
  • Garcia CR, Bau CH, Silva KL et al. The burdened life of adults with ADHD: impairment beyond comorbidity. Eur. Psychiatry 27(5), 309–313 (2012).
  • Brod M, Schmitt E, Goodwin M, Hodgkins P, Niebler G. ADHD burden of illness in older adults: a life course perspective. Qual. Life Res. 21(5), 795–799 (2012).
  • Gordon M, Antshel K, Faraone S et al. Symptoms versus impairment: the case for respecting DSM-IV’s Criterion D. J. Atten. Disord. 9(3), 465–475 (2006).
  • Gathje RA, Lewandowski LJ, Gordon M. The role of impairment in the diagnosis of ADHD. J. Atten. Disord. 11(5), 529–537 (2008).
  • Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J. Clin. Psychopharmacol. 30(2), 145–151 (2010).
  • Danckaerts M, Sonuga-Barke EJ, Banaschewski T et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur. Child Adolesc. Psychiatry 19(2), 83–105 (2010).
  • Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J; ADHD European Guidelines Group. Practitioner review: quality of life in child mental health – conceptual challenges and practical choices. J. Child Psychol. Psychiatry 50(5), 544–561 (2009).
  • Mannuzza S, Castellanos FX, Roizen ER, Hutchison JA, Lashua EC, Klein RG. Impact of the impairment criterion in the diagnosis of adult ADHD: 33-year follow-up study of boys with ADHD. J. Atten. Disord. 15(2), 122–129 (2011).
  • Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J. Psychopharmacol. (Oxford) 26(6), 753–765 (2012).
  • Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs 24(10), 843–866 (2010).
  • Surman C, Hammerness P, Pion K, Faraone S. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur. Neuropsychopharmacol. doi:10.1016/j.euroneuro.2012.02.010 (2013) (Epub ahead of print).
  • Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. Prim. Care Comp. CNS Disord. 14(6), e1–e15 (2012).
  • MTA (Multimodal Treatment Study of Children with ADHD) Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry. 56(12), 1073–1086 (1999).
  • NICE. Attention Deficit Hyperactivity Disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. The British Psychological Society and The Royal College of Psychiatrists, Leicester, UK (2009).
  • Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 82(4), 661–687 (2004).
  • Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J. Clin. Child Adolesc. Psychol. 34(3), 449–476 (2005).
  • Booster GD, DuPaul GJ, Eiraldi R, Power TJ. Functional impairments in children with ADHD: unique effects of age and comorbid status. J. Atten. Disord. 16(3), 179–189 (2012).
  • Katusic MZ, Voigt RG, Colligan RC, Weaver AL, Homan KJ, Barbaresi WJ. Attention-deficit hyperactivity disorder in children with high intelligence quotient: results from a population-based study. J. Dev. Behav. Pediatr. 32(2), 103–109 (2011).
  • Coghill D, Spiel G, Baldursson G et al.; ADORE Study Group. Which factors impact on clinician-rated impairment in children with ADHD? Eur. Child Adolesc. Psychiatry 15(Suppl. 1), I30–I37 (2006).
  • Hosenbocus S, Chahal R. A review of executive function deficits and pharmacological management in children and adolescents. J. Can. Acad. Child Adolesc. Psychiatry 21(3), 223–229 (2012).
  • Biederman J, Fried R, Hammerness P et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J. Psychiatr. Res. 46(4), 484–491 (2012).
  • Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 118(3), e704–e710 (2006).
  • Sobanski E, Sabljic D, Alm B et al. Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). J. Neural Transm. 115(2), 347–356 (2008).
  • Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J. Nerv. Ment. Dis. 188(4), 230–234 (2000).
  • Hodgkins P, Arnold LE, Shaw M et al. A systematic review of global publication trends regarding long-term outcomes of ADHD. Front. Psychiatry 2, 84 (2011).
  • Biederman J, Mick E, Spencer T, Surman C, Faraone SV. Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD. CNS Neurosci. Ther. 18(2), 126–132 (2012).
  • Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schwartz J. Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder. J. Clin. Psychopharmacol. 22(3), 267–274 (2002).
  • Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur. Child Adolesc. Psychiatry 21(9), 477–492 (2012).
  • Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22(3), 213–237 (2008).
  • Graham J, Banaschewski T, Buitelaar J et al.; European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD. Eur. Child Adolesc. Psychiatry 20(1), 17–37 (2011).
  • Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 9, 72 (2011).
  • Brams M, Moon E, Pucci M, López FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr. Med. Res. Opin. 26(8), 1809–1825 (2010).
  • Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad. Med. 120(3), 69–88 (2008).
  • Ramos-Quiroga JA, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 25(1), 17–36 (2011).
  • Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can. J. Clin. Pharmacol. 13(1), e50–e62 (2006).
  • Pelham WE Jr, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J. Clin. Child Adolesc. Psychol. 37(1), 184–214 (2008).
  • McGough JJ. Attention deficit hyperactivity disorder pharmacogenetics: the dopamine transporter and D4 receptor. Pharmacogenomics 13(4), 365–368 (2012).
  • Scassellati C, Bonvicini C, Faraone SV, Gennarelli M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J. Am. Acad. Child Adolesc. Psychiatry 51(10), 1003–1019.e20 (2012).
  • Erder MH, Signorovitch JE, Setyawan J et al. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J. Med. Econ. 15(6), 1078–1087 (2012).
  • Furey ML, Nugent AC, Speer AM et al. Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res. 196(1), 62–67 (2012).
  • Hall I. Conference scene: UK pharmacogenetics and stratified medicine network. Pharmacogenomics 13(1), 19–20 (2012).
  • Levin B, Thompson JL, Chakraborty B, Levy G, MacArthur R, Haley EC. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless Phase II/III design. Clin. Trials 8(4), 398–407 (2011).
  • Lu M, Freytag SO, Stricker H, Kim JH, Barton K, Movsas B. Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP trial). Contemp. Clin. Trials 32(3), 453–460 (2011).
  • Rockwood K, Howlett S, Stadnyk K, Carver D, Powell C, Stolee P. Responsiveness of goal attainment scaling in a randomized controlled trial of comprehensive geriatric assessment. J. Clin. Epidemiol. 56(8), 736–743 (2003).
  • Surman CB, Monuteaux MC, Petty CR et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J. Clin. Psychiatry 71(12), 1612–1616 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.